| Company Name | Daiichi Sankyo Taiwan Ltd. |
|---|---|
| Protocol Number | DS8201-TWMA-BC-4001 |
| Title of Study | A retrospective, non-interventional, multicenter study to estimate the prevalence of HER2-low and describe the standard-of-care, treatment patterns and outcome in real-world practice among unresectable and/or metastatic breast cancer patients with HER2-low status in Taiwan – the RetroBC-HER2L-TW Study. |
| Primary Objective | To understand the prevalence of HER2-low among HER2-negative unresectable/metastatic BC patients based on the rescoring of HER2 fixed tissue immunohistochemistry (IHC)-stained slides. |
| Number of Sites | 3 |
| Period of Study | From：16-Nov-2022 to：31-Dec-2023 |
| Number of Patients | 450人 |
| IRB Approval Date | National Cheng Kung University Hospital:16-Nov-2022 National Taiwan University Hospital:01-Dec-2022 Taipei Veterans General Hospital:31-Jan-2023 |
| Publication Plan / Date | 30-Jun-2024 |
